Second Sight Medical Products, Inc. (NASDAQ:EYES)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report released on Monday. They currently have a $5.00 target price on the medical device company’s stock. HC Wainwright’s price target would indicate a potential upside of 327.35% from the company’s previous close.

Separately, Zacks Investment Research upgraded shares of Second Sight Medical Products from a “sell” rating to a “hold” rating in a research report on Tuesday, October 10th.

Second Sight Medical Products (NASDAQ EYES) opened at $1.17 on Monday. Second Sight Medical Products has a 12-month low of $0.90 and a 12-month high of $2.83.

Second Sight Medical Products (NASDAQ:EYES) last announced its earnings results on Thursday, November 2nd. The medical device company reported ($0.12) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.02. Second Sight Medical Products had a negative net margin of 565.12% and a negative return on equity of 171.77%. The company had revenue of $1.61 million for the quarter, compared to analyst estimates of $1.54 million. research analysts anticipate that Second Sight Medical Products will post -0.55 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Second Sight Medical Products, Inc. (EYES) Stock Rating Reaffirmed by HC Wainwright” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/11/08/second-sight-medical-products-inc-eyes-stock-rating-reaffirmed-by-hc-wainwright.html.

An institutional investor recently raised its position in Second Sight Medical Products stock. Vanguard Group Inc. boosted its holdings in Second Sight Medical Products, Inc. (NASDAQ:EYES) by 0.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 843,462 shares of the medical device company’s stock after buying an additional 5,973 shares during the period. Vanguard Group Inc. owned approximately 1.50% of Second Sight Medical Products worth $1,062,000 as of its most recent SEC filing. 13.04% of the stock is currently owned by institutional investors and hedge funds.

Second Sight Medical Products Company Profile

Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.

Receive News & Stock Ratings for Second Sight Medical Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products Inc. and related stocks with our FREE daily email newsletter.